Idiopathic pulmonary fibrosis (IPF) is the most common of the interstitial pneumonias of
unknown etiology and the most aggressive interstitial lung disease (1). In this context, it is …

Is the Cart Before the Horse? pproximately 50,000 to 70,000 Americans develop idiopathic
pulmonary fibrosis (IPF) every year. This disorder, the most common of the interstitial …

Background Patients with idiopathic pulmonary fibrosis have progressive scarring of the
lung and usually die within four to five years after symptoms develop. Treatment with oral …

Idiopathic pulmonary fibrosis is a chronic condition of the lung parenchyma involving
progressive injury, inflammation, and fibrosis. Data collected from October 1988 through …

Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …

PURPOSE: Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive respiratory
insufficiency and a median survival of only 2-5 years. There is no therapy for IPF with …

Background Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known
efficacious therapy. Methods In a double-blind, multinational trial, we randomly assigned …

Idiopathic pulmonary fibrosis (IPF) is a disease with progressive and devastating
deterioration of lung function and a fatal prognosis, despite aggressive therapeutic attempts …

Objective: To examine the clinical aspects of idiopathic pulmonary fibrosis (IPF) and the
efficacy and safety of interferon gamma-1b (IFNγ− 1b) in its treatment. Data Sources …

Interferon (IFN)-γ was recently proposed as a treatment for idiopathic pulmonary fibrosis. We
report on four patients who developed acute respiratory failure with new alveolar opacities …